Scholarlink

Background <p>The Fred Hutchinson Cancer Center (FHCC) has developed a novel in-house method for ocular proton therapy by adapting a pencil beam scanning (PBS) beamline and using a commercial treatment planning system. This manuscript outlines the workflow from simulation to treatment delivery and presents our experiences with the initial 40 patients.</p> Methods <p>Key innovations of our treatment approach include in-house developed treatment chair and gaze localization systems, CT imaging for planning, and a Monte Carlo algorithm for dose calculation. We gathered data on patient characteristics, dose volume statistics, and total treatment time. Additionally, we examined the distances patients traveled to access ocular proton therapy. An example illustrating our treatment technique is also presented.</p> Results <p>The average patient age at the time of treatment was 63.9 years. Tumor apical height ranged from 0.7 to 11.9&#xa0;mm, and the largest basal diameter from 2.8 to 15.5&#xa0;mm. GTV volumes ranged from 0.02 to 0.89&#xa0;cc, while PTV volumes ranged from 0.17 to 2.27&#xa0;cc. The D99% dose to GTV ranged from 5041 to 5242&#xa0;cGy (RBE). The median mean dose to the lacrimal gland was 1570&#xa0;cGy (RBE), while the median D2% doses to the optic nerve, macula, and optic disc were 4188&#xa0;cGy (RBE), 5024&#xa0;cGy (RBE), and 5133&#xa0;cGy (RBE), respectively. Out of the 40 patients, 16 successfully met all treatment planning goals. The remaining patients did not meet some goals due to the target either abutting or being close (&lt; 2&#xa0;mm) laterally or distally to the OARs. The total treatment duration per fraction was approximately 25&#xa0;min. Nearly one-third of the patients traveled around 900 miles to receive ocular treatment.</p> Conclusions <p>The approach at FHCC demonstrates that ocular proton therapy can be effectively delivered using a general-purpose PBS beamline, providing a solution for centers without dedicated ocular beamlines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Implementing ocular treatment with pencil beam scanning: the FHCC experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Jatinder Saini,
  • Andrew Stacey,
  • Alexander Egan,
  • Rajesh Regmi,
  • Charles Bloch,
  • Marco Schwarz,
  • Ramesh Rengan,
  • Jonathan Chen,
  • Lia Halasz

摘要

Background

The Fred Hutchinson Cancer Center (FHCC) has developed a novel in-house method for ocular proton therapy by adapting a pencil beam scanning (PBS) beamline and using a commercial treatment planning system. This manuscript outlines the workflow from simulation to treatment delivery and presents our experiences with the initial 40 patients.

Methods

Key innovations of our treatment approach include in-house developed treatment chair and gaze localization systems, CT imaging for planning, and a Monte Carlo algorithm for dose calculation. We gathered data on patient characteristics, dose volume statistics, and total treatment time. Additionally, we examined the distances patients traveled to access ocular proton therapy. An example illustrating our treatment technique is also presented.

Results

The average patient age at the time of treatment was 63.9 years. Tumor apical height ranged from 0.7 to 11.9 mm, and the largest basal diameter from 2.8 to 15.5 mm. GTV volumes ranged from 0.02 to 0.89 cc, while PTV volumes ranged from 0.17 to 2.27 cc. The D99% dose to GTV ranged from 5041 to 5242 cGy (RBE). The median mean dose to the lacrimal gland was 1570 cGy (RBE), while the median D2% doses to the optic nerve, macula, and optic disc were 4188 cGy (RBE), 5024 cGy (RBE), and 5133 cGy (RBE), respectively. Out of the 40 patients, 16 successfully met all treatment planning goals. The remaining patients did not meet some goals due to the target either abutting or being close (< 2 mm) laterally or distally to the OARs. The total treatment duration per fraction was approximately 25 min. Nearly one-third of the patients traveled around 900 miles to receive ocular treatment.

Conclusions

The approach at FHCC demonstrates that ocular proton therapy can be effectively delivered using a general-purpose PBS beamline, providing a solution for centers without dedicated ocular beamlines.